Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 132

1.

Immunotherapy for kidney cancer: status quo and the future.

Bedke J, Stühler V, Stenzl A, Brehmer B.

Curr Opin Urol. 2017 Nov 7. doi: 10.1097/MOU.0000000000000466. [Epub ahead of print]

PMID:
29120911
2.

Impact of variant microscopic interpretation of the uCyt+ immunocytological urine test for the detection of bladder cancer.

Deininger S, Todenhöfer T, Hennenlotter J, Gerber V, Schwarz J, Bedke J, Schwentner C, Stenzl A, Rausch S.

Diagn Cytopathol. 2017 Nov 8. doi: 10.1002/dc.23857. [Epub ahead of print]

PMID:
29115014
3.

Imaging response assessment of immunotherapy in patients with renal cell and urothelial carcinoma.

Weiss J, Notohamiprodjo M, Bedke J, Nikolaou K, Kaufmann S.

Curr Opin Urol. 2017 Oct 27. doi: 10.1097/MOU.0000000000000463. [Epub ahead of print]

PMID:
29083998
4.

Results of a Phase 1/2 Study in Metastatic Renal Cell Carcinoma Patients Treated with a Patient-specific Adjuvant Multi-peptide Vaccine after Resection of Metastases.

Rausch S, Gouttefangeas C, Hennenlotter J, Laske K, Walter K, Feyerabend S, Chandran PA, Kruck S, Singh-Jasuja H, Frick A, Kröger N, Stevanović S, Stenzl A, Rammensee HG, Bedke J.

Eur Urol Focus. 2017 Oct 4. pii: S2405-4569(17)30213-4. doi: 10.1016/j.euf.2017.09.009. [Epub ahead of print]

PMID:
28988765
5.

[TKI 2.0 - changes in the medical treatment of renal cell carcinoma].

Stühler V, Kruck S, Hegemann M, Notohamiprodjo M, Todenhöfer T, Kröger N, Stenzl A, Bedke J.

Urologe A. 2017 Sep 6. doi: 10.1007/s00120-017-0496-z. [Epub ahead of print] Review. German.

PMID:
28879504
6.

Circulating tumor cells and their role in prostate cancer.

Maas M, Hegemann M, Rausch S, Bedke J, Stenzl A, Todenhöfer T.

Asian J Androl. 2017 Aug 22. doi: 10.4103/aja.aja_29_17. [Epub ahead of print] Review.

7.

Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice.

Bedke J, Heide J, Ribback S, Rausch S, de Martino M, Scharpf M, Haitel A, Zimmermann U, Pechoel M, Alkhayyat H, Shariat SF, Dombrowski F, Stenzl A, Burchardt M, Klatte T, Kroeger N.

BJU Int. 2017 Aug 13. doi: 10.1111/bju.13984. [Epub ahead of print]

PMID:
28803448
8.

Effect of radical prostatectomy on levels of cancer related epitopes in circulating macrophages of patients with clinically localized prostate cancer.

Todenhöfer T, Hennenlotter J, Keller G, Neumann T, Stenzl A, Bedke J.

Prostate. 2017 Sep;77(12):1251-1258. doi: 10.1002/pros.23384. Epub 2017 Jul 20.

PMID:
28726251
9.

The thermoexpandable nitinol stent: a long-term alternative in patients without nephropathy or malignancy.

Bier S, Amend B, Wagner E, Rausch S, Mischinger J, Neumann E, Stühler V, Hennenlotter J, Todenhoefer T, Stenzl A, Bedke J, Kruck S.

Scand J Urol. 2017 Oct;51(5):388-391. doi: 10.1080/21681805.2017.1331262. Epub 2017 Jun 23.

PMID:
28644054
10.

[An open single-arm phase II monotherapy study of pembrolizumab (MK-3475) in locally advanced/metastatic renal cell carcinoma (mRCC) (Keynote 427) - AN 40/16 of the AUO].

Rexer H, Doehn C, Bedke J.

Urologe A. 2017 Jul;56(7):928-929. doi: 10.1007/s00120-017-0422-4. German. No abstract available.

PMID:
28616640
11.

Chronic Periodontitis Does Not Impact Serum Levels of Prostate-specific Antigen.

Kruck S, Hennenlotter J, Amend B, Geiger M, Filipova E, Neumann T, Stühler V, Schubert T, Todenhöfer T, Rausch S, Huettig F, Stenzl A, Bedke J.

Anticancer Res. 2017 Jun;37(6):3163-3167.

PMID:
28551659
12.

Comment on "Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin".

Winter S, Fisel P, Büttner F, Nies AT, Stenzl A, Bedke J, Schwab M, Schaeffeler E.

Sci Transl Med. 2017 May 24;9(391). pii: eaal2439. doi: 10.1126/scitranslmed.aal2439. No abstract available.

PMID:
28539468
13.

Immune Checkpoint Inhibition in Metastatic Urothelial Cancer.

Powles T, Smith K, Stenzl A, Bedke J.

Eur Urol. 2017 Oct;72(4):477-481. doi: 10.1016/j.eururo.2017.03.047. Epub 2017 Apr 14.

PMID:
28413128
14.

Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience.

Hegemann M, Bedke J, Stenzl A, Todenhöfer T.

Ther Adv Urol. 2017 Feb 6;9(3-4):81-88. doi: 10.1177/1756287216686018. eCollection 2017 Mar-Apr. Review.

15.

[Imaging of Metastastic Renal Cell Carcinoma under Therapy with Immune Checkpoint Inhibitors].

Notohamiprodjo M, Kopp HG, Bedke J.

Rofo. 2017 Apr;189(4):287-292. doi: 10.1055/s-0043-100511. Epub 2017 Mar 23. Review. German. No abstract available.

PMID:
28335045
16.

Prediction of Postoperative Risks in Laparoscopic Partial Nephrectomy Using RENAL, Mayo Adhesive Probability and Renal Pelvic Score.

Bier S, Aufderklamm S, Todenhöfer T, Kruck S, Schuster K, Rausch S, Othman A, Notohamiprodjo M, Nikolaou K, Schwentner C, Stenzl A, Bier G, Bedke J.

Anticancer Res. 2017 Mar;37(3):1369-1373.

PMID:
28314305
17.

The Value and Evaluability of the PCA3 Urine Assay in Prostate Carcinoma is Independent of the Tumor Localization.

Neumann E, Hennenlotter J, Todenhöfer T, Scharpf M, Neumann T, Schilling D, Stenzl A, Bedke J.

Adv Ther. 2017 Apr;34(4):966-974. doi: 10.1007/s12325-017-0510-2. Epub 2017 Mar 13.

PMID:
28290096
19.

Feasibility of accelerated simultaneous multislice diffusion-weighted MRI of the prostate.

Weiss J, Martirosian P, Taron J, Othman AE, Kuestner T, Erb M, Bedke J, Bamberg F, Nikolaou K, Notohamiprodjo M.

J Magn Reson Imaging. 2017 Nov;46(5):1507-1515. doi: 10.1002/jmri.25665. Epub 2017 Feb 15.

PMID:
28199041
20.

Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?

Anselmo Da Costa I, Rausch S, Kruck S, Todenhöfer T, Stenzl A, Bedke J.

Expert Rev Anticancer Ther. 2017 Apr;17(4):357-368. doi: 10.1080/14737140.2017.1292138. Epub 2017 Feb 20. Review.

PMID:
28162024

Supplemental Content

Loading ...
Support Center